课题基金 / 基金详情

Phase II studies of gamma tocopherol as an intervention for environmental asthma

Phase II studies of gamma tocopherol as an intervention for environmental asthma
γ-生育酚作为环境性哮喘干预措施的 II 期研究
批准号:
8598698
负责人:
David B. Peden
金额:
$52.61万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-12 至 2018-04-30
关键词:
AcuteAir PollutantsAir PollutionAllergensAllergicAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntibiotic A23187AntioxidantsArachidonate 5-LipoxygenaseAsthmaBasophilsBiologicalBiological MarkersBiomassBreathingCellsChronicCytokine SignalingDNADataDehydrationDevelopmentDoseDouble-Blind MethodEndotoxinsEnrollmentEosinophiliaEpidemiologic StudiesEpithelial CellsExhalationExtrinsic asthmaGSTM1 geneGene ProteinsGenotypeGoalsHomozygoteHourHumanIgEInflammationInflammatoryInflammatory ResponseInterleukin-13InterventionLOX geneLipidsLipopolysaccharidesLungLung diseasesMAPK3 geneMediatingMediator of activation proteinModelingMorbidity - disease rateMucinsMucociliary ClearanceMucous body substanceNeutrophiliaNitrogenNutritionalOxidantsOxygenOzoneParticipantParticulatePathologicPeripheral Blood Mononuclear CellPeroxonitritePhasePhosphorylationPlacebo ControlPlasmaPopulationPreparationProductionProstaglandin-Endoperoxide SynthaseProtein IsoformsProteinsProtocols documentationPublic HealthReactive Oxygen SpeciesRecruitment ActivityReportingRespiratory SystemRespiratory tract structureRiskRisk FactorsRodentRodent ModelRoleSamplingSerumSignal TransductionSmokeSourceSputumStressSupplementationTestingTherapeuticTissuesTobaccoTocopherolsUnited StatesVariantVitamin Eairway inflammationcostcost effectivecytokinedesignefficacy testingenvironmental interventioneosinophileosinophilic inflammationgamma-Tocopherolgranulocytehealthy volunteerhuman CCL26 proteininjured airwaymonocyteneutrophilnovelphase 2 studyphase 3 studyplacebo controlled studypollutantpreventpublic health relevancerandomized placebo controlled trialresponsevolunteer

项目摘要

项目成果

David B. Peden的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Allergic asthma (AA) is the most commonly encountered respiratory disease in the United States and is a leading cause of morbidity worldwide The goals of this project are to undertake phase IIa studies of a gamma tocopherol enriched mixed tocopherol (?T-mT) preparation on chronic eosinophilic inflammation and acute increases in neutrophilic inflammation in allergic asthmatics (AAs) associated with LPS and O3 challenge. Endotoxin (lipopolysaccharide or LPS) is a component of coarse and fine mode PM, bioaerosols, tobacco and biomass smoke. Ozone (O3) is the most commonly encountered ambient air pollutant in the US. Epidemiological studies have shown that both LPS and O3 are important asthma triggers. In challenge studies of AAs, we have shown that LPS and O3 induces influx of neutrophils (PMNs) and eosinophils in AAs as well as augmenting response to inhaled allergens. O3 is also an oxidant, and both O3 and LPS increase radical production by airway cells, with both nutritional and genetically defined antioxidant deficiencies (such as the GSTM1 null genotype) being associated with increased risk for pollutant-induced asthma exacerbation. In challenge studies, we have reported that LPS and O3 PMN responses are increased in GSTM1 null volunteers. Gamma tocopherol has known antioxidant and anti-inflammatory actions. We have shown that ?T prevents allergen, O3 and LPS-induced respiratory tract inflammation in rodents. Our phase I human studies with ?T-mT established a dose which maintains ?T and its anti-inflammatory metabolites, decreases monocyte responses to LPS and IgE-mediated basophil response to allergen. Data from our initial double-blinded, placebo controlled phase IIa study in healthy volunteers demonstrates that ?T-mT inhibits LPS-induced granulocyte influx. Successful completion of this phase IIa study in AAs will guide development of a phase III efficacy study of this low cost nutriceutical intervention for preventio of pollutant-induced asthma exacerbations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research Training in Allergy and Clinical Immunology
Research Training in Allergy and Clinical Immunology
Project 4: Treatment of mucostasis and airways obstruction in asthma with a novel mucolytic
Project 4: Treatment of mucostasis and airways obstruction in asthma with a novel mucolytic
海外基金